DRRX - DURECT Corporation
| Previous Close | 1.9600 |
| Open | 1.9500 |
| Bid | 1.9400 x 1800 |
| Ask | 2.1200 x 1100 |
| Day's Range | 1.9300 - 2.0300 |
| 52 Week Range | 0.4600 - 2.4600 |
| Volume | 563,474 |
| Avg. Volume | 1,171,027 |
| Market Cap | 381.965M |
| Beta (3Y Monthly) | 1.40 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.1510 |
| Earnings Date | Nov 1, 2018 - Nov 2, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.59 |
- American City Business Journals
These 24 Bay Area drug and diagnostics companies quietly raised nearly $3B this year
While initial public offerings get most of the splash, public companies also are raking in cash with follow-on offerings. How long will the Wall Street spigot stay open?
- PR Newswire
DURECT to Present at Two Upcoming NASH Investor Conferences
CUPERTINO, Calif. , Oct. 17, 2019 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will be presenting at two upcoming investor conferences focused on non-alcoholic steatohepatitis ...
- PR Newswire
DURECT Announces Completion of Enrollment in its Phase 2a Clinical Trial of DUR-928 in Psoriasis and 50% Enrollment in its Phase 1b DUR-928 Clinical Trial in NASH
CUPERTINO, Calif., Oct. 7, 2019 /PRNewswire/ -- DURECT Corporation (DRRX) today announced that it has completed enrollment in its Phase 2a clinical trial of topical DUR-928 in patients with mild to moderate plaque psoriasis. The company also announced that it has now enrolled 30 of the planned 60 patients in its ongoing Phase 1b trial with oral DUR-928 in patients with non-alcoholic steatohepatitis (NASH). "We are pleased that on the heels of completing the alcoholic hepatitis trial on schedule and announcing positive results, we have also achieved important enrollment milestones in our ongoing psoriasis and NASH trials," said James E. Brown, President and CEO of DURECT.
- PR Newswire
DURECT Announces FDA Advisory Committee Meeting to Review POSIMIR® for the Treatment of Post-Surgical Pain
CUPERTINO, Calif., Oct. 2, 2019 /PRNewswire/ -- DURECT Corporation (DRRX) announced today that the U.S. Food and Drug Administration (FDA) has notified the Company that its Class 2 NDA resubmission for POSIMIR® (bupivacaine extended-release solution) will be discussed at a meeting of the Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC). DURECT commissioned the advisory services of Dr. Lee S. Simon to lead the Company's preparation efforts to prepare for the advisory committee meeting.
- PR Newswire
DURECT to Present at the 2019 Cantor Fitzgerald Global Health Care Conference
CUPERTINO, Calif., Sept. 26, 2019 /PRNewswire/ -- DURECT Corporation (DRRX) announced today that James E. Brown, Chief Executive Officer will be presenting at the Cantor Fitzgerald Global Health Care Conference, at the InterContinental New York Barclay Hotel on Friday, October 4, 2019 at 10:40 a.m. EDT. Institutional investors and analysts that are attending the conference may request a one-on-one meeting through the conference coordinators. The live audio webcast of the presentation will also be available by accessing DURECT's homepage at www.durect.com and clicking on the "Investors" tab. If you are unable to participate during the live webcast, the call will be archived on DURECT's website in the "Event Calendar" of the "Investors" section.
- Benzinga
The Daily Biotech Pulse: NewLink Genetics Rallies, Breakthrough Designation For Roche, IGM Biosciences Debuts
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Sept. 17.) 10X Genomics Inc (NASDAQ: TXG ) (listed ...
- PR Newswire
DURECT Announces Positive Data from its Phase 2a Clinical Trial of DUR-928 in Alcoholic Hepatitis
CUPERTINO, Calif. , Sept. 17, 2019 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it has completed the Phase 2a clinical trial of its lead product candidate, DUR-928, in patients ...
- PR Newswire
DURECT Earns $10 Million Milestone Payment for Further Development of a Long-Acting Injectable HIV Investigational Product Utilizing DURECT's SABER® Technology
CUPERTINO, Calif., Sept. 9, 2019 /PRNewswire/ -- DURECT Corporation (DRRX) announced today that further development of a long-acting injectable HIV investigational product utilizing DURECT's SABER® technology has triggered a $10 million milestone payment from Gilead Sciences, Inc. to DURECT under the license agreement between the companies. "We are pleased that Gilead has been rapidly advancing this program," stated James E. Brown, President and CEO of DURECT.
- Motley Fool
3 Biotech Stocks That Could Double Your Money
Hardly anyone's heard of these drugmakers, but some analysts think they could be top performers.
- Motley Fool
Why Durect Stock Is Up Today
Investors bid up the share price after the company received some bullish praise from a Wall Street pro.
- PR Newswire
DURECT to Present at the 21st Annual Rodman and Renshaw Global Investment Conference Sponsored by H.C. Wainwright
CUPERTINO, Calif., Sept. 4, 2019 /PRNewswire/ -- DURECT Corporation (DRRX) announced today that James E. Brown, Chief Executive Officer will be presenting at the 21st Annual Global Rodman and Renshaw Investment Conference, sponsored by H. C. Wainwright, at the Lotte New York Palace Hotel in New York on Monday, September 9, 2019 at 11:40 a.m. EDT. Institutional investors and analysts that are attending the conference may request a one-on-one meeting through the conference coordinators. The live audio webcast of the presentation will also be available by accessing DURECT's homepage at www.durect.com and clicking on the "Investors" tab. If you are unable to participate during the live webcast, the call will be archived on DURECT's website in the "Event Calendar" of the "Investors" section.
- Thomson Reuters StreetEvents
Edited Transcript of DRRX earnings conference call or presentation 1-Aug-19 8:30pm GMT
Q2 2019 DURECT Corp Earnings Call
- Zacks Small Cap Research
DRRX: Gilead Agreement, Near-Term Value-Inflection Opportunities Make DRRX Particularly Attractive at Current Valuation
Durect Corp (DRRX) reported financial results for their second quarter ending June 30th and provided a pipeline development update. ‣ Gilead, HIV/HBV-SABER licensing agreement: on July 22nd DRRX announced an out-licensing agreement with Gilead Sciences, Inc (GILD) related to their SABER (controlled drug delivery) technology in the development of a long-acting injectable HIV product. The agreement, which will pay DRRX $25M upfront and potentially up to another $145M in development and sales related milestones (in addition to tiered royalties on sales) for the initial injectable HIV product, comes after ~two years’ worth of feasibility related work between the parties.
- PR Newswire
DURECT Corporation Announces Second Quarter 2019 Financial Results and Update of Programs
Live Webcast of Earnings Call Today at 4:30 p.m. Eastern Time CUPERTINO, Calif. , Aug. 1, 2019 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended ...
- PR Newswire
DURECT Corporation to Announce Second Quarter 2019 Financial Results on August 1
CUPERTINO, Calif. , July 25, 2019 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it will report second quarter and six months ended June 30, 2019 financial results and host a conference ...
- Market Realist
Why Durect Corporation Is Soaring Today
On July 22, Durect Corporation (DRRX) entered into a collaboration with HIV leader Gilead Sciences (GILD).
- PR Newswire
DURECT and Gilead Enter into License Agreement for Long-Acting Injectable HIV Investigational Product
CUPERTINO, Calif., July 22, 2019 /PRNewswire/ -- DURECT Corporation (DRRX) announced today that it has entered into an agreement with Gilead Sciences, Inc. granting Gilead the exclusive worldwide rights to develop and commercialize a long-acting injectable HIV product utilizing DURECT's SABER® technology. Gilead also received exclusive access to the SABER® platform for HIV and Hepatitis B Virus (HBV) and the exclusive option to license additional SABER-based products directed to HIV and HBV. "We're pleased to be working on this program with Gilead given their expertise and global leadership in the HIV and HBV fields," stated James E. Brown, President and CEO of DURECT.
- PR Newswire
DURECT Announces that the FDA Agreed to File the Full Response to the POSIMIR® Complete Response Letter as a Complete Class 2 Resubmission
CUPERTINO, Calif., July 17, 2019 /PRNewswire/ -- DURECT Corporation (DRRX) today announced that the U.S. Food and Drug Administration (FDA) has acknowledged that the submission of DURECT's full response to the Complete Response Letter (CRL) it previously received from FDA related to POSIMIR® (bupivacaine extended-release solution) is considered by the FDA to be a complete class 2 response to the CRL. The user fee goal date is December 27, 2019. The submission is intended to address the issues raised in the CRL and seeks FDA approval of POSIMIR based on what the Company and its advisors believe is adequate evidence of both safety and efficacy. DURECT commissioned the advisory services of Dr. Lee S. Simon to first evaluate the adequacy of the existing POSIMIR package to address the issues raised in FDA correspondence, including the CRL, and then to lead the Company's efforts to submit its response to the CRL.
- Zacks Small Cap Research
DRRX: Favorable FDA Decision on POSIMIR Would Likely Mean Significant Upside to Our Model
This morning, Durect (DRRX) announced that they submitted a full response to FDA’s Complete Response Letter for POSIMIR, which Durect received in February 2014. POSIMIR is the company’s investigational post-operative pain relief depot that utilizes the company’s patented SABER technology and is intended to deliver bupivacaine to provide three days of pain relief after surgery. As a reminder DRRX submitted an NDA ((via 505(b)(2) pathway)) to FDA for POSIMIR in April 2013.
- PR Newswire
DURECT Announces Submission to FDA of a Full Response to the POSIMIR® Complete Response Letter
CUPERTINO, Calif., June 27, 2019 /PRNewswire/ -- DURECT Corporation (DRRX) today announced it has submitted a full response to the Complete Response Letter (CRL) it previously received from U.S. Food and Drug Administration (FDA) related to POSIMIR® (bupivacaine extended-release solution). The submission is intended to address the issues raised in the CRL and seeks FDA approval of POSIMIR based on what the Company and its advisors believe is adequate evidence of both safety and efficacy. DURECT commissioned the advisory services of Dr. Lee S. Simon to first evaluate the adequacy of the existing POSIMIR package to address the issues raised in FDA correspondence, including the CRL, and then to lead the Company's efforts to submit its response to the CRL. Dr. Simon is a physician and research scientist who served as the FDA's Division Director of Analgesic, Anti-inflammatory and Ophthalmologic Drug Products from 2001 to 2003, and is now a Principal at SDG, LLC, an FDA advisory firm.
- Benzinga
The Daily Biotech Pulse: Decision Day For Regeneron-Sanofi, Vermillion Offering, PDL BioPharma CFO to Depart
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 25) ArQule, Inc. (NASDAQ: ARQL ) Zai Lab Ltd (NASDAQ: ZLAB ...
- PR Newswire
DURECT Receives Approval from Nasdaq for Transfer of Listing to Nasdaq Capital Market
CUPERTINO, Calif., June 25, 2019 /PRNewswire/ -- DURECT Corporation (DRRX) today announced that it received approval from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq") to transfer the listing of the Company's common stock from the Nasdaq Global Market to the Nasdaq Capital Market, effective June 27, 2019. To regain compliance with the Minimum Bid Price Requirement and qualify for continued listing on the Nasdaq Capital Market, the minimum bid price per share of the Company's common stock must be at least $1.00 for at least ten consecutive business days during the additional 180-day grace period. If the Company does not regain compliance during this additional grace period, its common stock would be subject to delisting by Nasdaq. As part of its transfer application, the Company notified Nasdaq that if the stock price does not recover sufficiently during the additional grace period, it would implement a reverse stock split, if necessary.
- PR Newswire
DURECT Announces $15 Million Registered Direct Offering
CUPERTINO, Calif., June 20, 2019 /PRNewswire/ -- DURECT Corporation ("DURECT" or the "Company") (DRRX) today announced that it has entered into a securities purchase agreement with certain investors pursuant to which, subject to the terms and conditions expressed therein, the Company agreed to sell and the investors agreed to purchase 29,000,000 shares of common stock of the Company at a price per share of $0.52. The net proceeds, after estimated expenses of the offering payable by the Company, will be approximately $15.0 million. No placement agent or broker dealer was used or participated in the offering.
- PR Newswire
DURECT Announces Completion of the 90 mg Severe Cohort and Dose Escalation Committee Approval to Commence 150 mg Dosing in Patients with Severe Alcoholic Hepatitis (AH) in its Ongoing DUR-928 Phase 2a AH Trial
CUPERTINO, Calif. , June 18, 2019 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it has completed dosing the 90 mg cohort of severe AH patients in its ongoing DUR-928 Phase 2a clinical ...
